Literature DB >> 12496894

Gene therapy for prostate cancer.

J Naitoh1, A Belldegrun.   

Abstract

The treatment options for the patient with advanced prostate cancer are limited. Due to the recent advances in the understanding of the molecular biology of prostate cancer, the easy accessibility of the gland for injection, and the availability of gene promoters that can provide tissue specific expression of therapeutic gene sequences, gene therapy for prostate cancer is rapidly advancing. Many potential approaches for prostate cancer gene therapy have been identified, with a few of these already entering Phase I clinical trials. This review will discuss the basis of prostate cancer gene therapy, look at the potential approaches, and will compare the different vectors that can be used to deliver the therapeutic genes to the prostate tumor.

Entities:  

Year:  1998        PMID: 12496894     DOI: 10.1038/sj.pcan.4500242

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  2 in total

1.  Prostate cancer gene therapy-what have we learned and where are we going?

Authors:  B Djavan; Y Nasu
Journal:  Rev Urol       Date:  2001

2.  Mesenchymal stem cells modified to express lentivirus TNF-α Tumstatin(45-132) inhibit the growth of prostate cancer.

Authors:  Xu Zhang; Wenrong Xu; Hui Qian; Wei Zhu; Ruiwen Zhang
Journal:  J Cell Mol Med       Date:  2011-02       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.